# BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

> **NCT04236011** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shanghai Changzheng Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** GC012F injection

## Key facts

- **NCT ID:** NCT04236011
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-16
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2021-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04236011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04236011, "BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04236011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*